Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Dolutegravir

Dolutegravir

Dolutegravir is an integrase inhibitor used to treat HIV infection.
It interfers with the HIV integrase enzyme, preventing the virus from inserting its genetic material into the host cell's DNA.
Dolutegravir is often used in combination with other antiretroviral medications to supress HIV viral load and slow disease progression.
Researchers use advanced AI-driven analysis to identify the most effective and reproduciblee Dolutegravir research protocols from literature, pre-prints, and patents, streamlining research and enhancing discoveries.

Most cited protocols related to «Dolutegravir»

1
Antiretroviral Efficacy and Safety in Treatment-Naive HIV-1 Patients
Cited 9 times
The PubMed/MEDLINE, Embase, and Cochrane databases were systematically searched (up to August 2013) to identify randomized controlled trials (RCTs) evaluating efficacy and/or safety of ATV/r, DRV/r, DTG, EFV, EVG/c, LPV/r, RAL, or RPV in treatment-naive HIV-1 patients. PubMed and EMBASE search terms were “HIV-1 [mesh] OR HIV infections [mesh] NOT pregnancy [mesh] AND ((dolutegravir OR GSK1349572) OR (efavirenz OR Sustiva OR Stocrin OR DMP-266) OR (raltegravir OR Isentress OR MK-0518) OR (elvitegravir OR GS-9137 OR JTK-303) OR (rilpivirine OR Edurant OR TMC 278) OR (darunavir OR Prezista OR TMC-114) OR (atazanavir OR Reyataz OR BMS-232632) OR (lopinavir OR ABT-378 OR Aluviran OR Koletra OR Kaletra) OR (Atripla OR Quad OR Stribild OR Eviplera OR Complera))”. The ClinicalTrials.gov registry, US FDA summary basis of approvals, EMA EPAR scientific discussions, and references of published systematic reviews and meta-analyses were also searched for any additional data. Abstracts of the 2013 meeting of the International AIDS Society and the Interscience Conference on Antimicrobial Agents and Chemotherapy were searched to identify recent presentations. Two phase 3 studies of DTG with data available after August 2013 were also included.
Study selection was conducted by two independent researchers who performed an initial review and selection of study titles/abstracts followed by full text review and selection. Disagreements between the reviewers were resolved by consensus. Pre-specified inclusion criteria included treatment-naive patients with HIV-1 infection; studies published in English; phase 3 or 4 RCT; patients aged ≥13 years; use of at least one of the third agents of interest; and reporting at least one of the efficacy outcomes of interest after 48 weeks of treatment. Non-randomized observational studies; single-arm studies; and studies examining different dosages of the same drug, structured treatment interruptions, maintenance treatments, or treatment switching were excluded, as were publications where outcomes specific to a treatment-naive population could not be distinguished. Studies reporting outcomes such that results could not be obtained for each treatment arm individually were also excluded. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed through all phases in the study [14] (link).
Three researchers independently abstracted data from the final selection of studies into a structured Microsoft Access database and data were reconciled for accuracy. The Effective Public Health Practice Project Quality Assessment, a quality assessment tool, was used to assess selection bias, study design, confounders, blinding, data collection methods, and withdrawals and dropouts [15] (link).
Patel D.A., Snedecor S.J., Tang W.Y., Sudharshan L., Lim J.W., Cuffe R., Pulgar S., Gilchrist K.A., Camejo R.R., Stephens J, & Nichols G. (2014). 48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis. PLoS ONE, 9(9), e105653.
Full text: Click here
Publication 2014
ABT 378 Acquired Immunodeficiency Syndrome Aftercare Atazanavir Atripla BMS 232632 Complera Conferences Darunavir DMP 266 efavirenz elvitegravir GS 9137 HIV-1 HIV Infections Infection Isentress JTK-303 Kaletra Lopinavir Microbicides MK 0518 Patients Pharmaceutical Preparations Pharmacotherapy Pregnancy Prezista Raltegravir Reyataz Rilpivirine Safety Stocrin Stribild Sustiva TMC 114 TMC 278
2
Dolutegravir-Induced Changes in Depression
Cited 8 times
Results were reported as median and interquartile range (IQR) or frequency and percentage, as appropriate. Plasma viral suppression was defined as HIV-1 RNA < 50 copies/ml. McNemar and Wilcoxon signed-rank tests were used, as appropriate, to compare the outcomes before and after DTG. Multivariate linear regression examined factors that were correlated with the change in PHQ-9 scores between the 1st and 2nd assessment. Statistical analyses were performed using SPSS Version 18.0 (IBM Corp., Armonk, NY).
Chan P., Goh O., Kroon E., Colby D., Sacdalan C., Pinyakorn S., Prueksakaew P., Reiss P., Ananworanich J., Valcour V., Spudich S, & Paul R. (2020). Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. AIDS Research and Therapy, 17, 1.
Full text: Click here
Publication 2020
HIV-1 Plasma
3
Community-wide HIV testing and treatment
Cited 7 times
The intervention strategy included communitywide, standardized, home-based and mobile HIV testing campaigns, enhancement of routine testing in health facilities (e.g., with placement of additional staff members for HIV testing and an emphasis on the importance of routine testing), and targeted outreach testing of all men (regardless of age) and young persons (men and women ≤25 years of age), as well as active linkage to care at local clinics for HIV-positive persons who were not receiving ART (with an appointment scheduled within 1 week, a text message reminder before the appointment, and active tracing if the appointment was missed). In addition, until August 2015, expanded ART was provided for participants with an HIV type 1 (HIV-1) RNA level of 10,000 copies per milliliter or more (if the CD4 count was >350 cells per cubic millimeter); from August 2015 through May 2016, ART was provided for participants with a CD4 count of 500 cells per cubic millimeter or less or an HIV-1 RNA level of 10,000 copies per milliliter or more (if the CD4 count was >500 cells per cubic millimeter). Starting in June 2016, universal ART (treatment eligibility for all persons with a diagnosis of HIV infection, regardless of the CD4 count or HIV-1 RNA level) was initiated at the first clinic visit. Increased access to male circumcision services (mobilization campaigns, mobile clinics, and peer linkage with scheduled appointments, reminders, and transportation) was also provided.
In all 30 communities, from the initiation of the trial until June 2016, HIV-positive persons who had a CD4 count of 350 cells per cubic millimeter or less or World Health Organization (WHO) stage III or IV disease, as well as those who were pregnant or breast-feeding, were eligible to receive ART. After June 2016, universal ART was offered in both the intervention and standard-care groups.
All the communities implemented the relevant changes in the ART eligibility criteria simultaneously. In the communities in the intervention group, participants who were eligible to receive ART according to the revised criteria were contacted and referred. Beginning in June 2016, the first-line ART regimen provided by the government to all trial communities was switched from efavirenz–tenofovir disoproxil fumarate (TDF)–emtricitabine (FTC) to dolutegravir–TDF-FTC. Persons who moved into communities in the intervention group were eligible for all interventions. Noncitizens were eligible only for free HIV testing. Interventions were provided by cadres of staff who were typically employed in the region, and ART was provided in public clinics by government staff.
Makhema J., Wirth K.E., Holme M.P., Gaolathe T., Mmalane M., Kadima E., Chakalisa U., Bennett K., Leidner J., Manyake K., Mbikiwa A.M., Simon S.V., Letlhogile R., Mukokomani K., van Widenfelt E., Moyo S., Lebelonyane R., Alwano M.G., Powis K.M., Dryden-Peterson S.L., Kgathi C., Novitsky V., Moore J., Bachanas P., Abrams W., Block L., El-Halabi S., Marukutira T., Mills L.A., Sexton C., Raizes E., Gaseitsiwe S., Bussmann H., Okui L., John O., Shapiro R.L., Pals S., Michael H., Roland M., DeGruttola V., Lei Q., Wang R., Tchetgen E.T., Essex M, & Lockman S. (2019). Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. The New England journal of medicine, 381(3), 230-242.
Publication 2019
CD4+ Cell Counts Cells Clinic Visits Cuboid Bone dolutegravir Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Eligibility Determination HIV-1 HIV Infection Diagnosis HIV Seropositivity Male Circumcision Tenofovir Disoproxil Fumarate Treatment Protocols Woman
4
Estimating Health Impacts of Policies
Cited 6 times
Our primary measure of health outcome was disability adjusted life-years (DALYs). Although we explicitly modelled the individual life courses of adults only, we considered DALY effects of neural tube defects and of mother-to-child HIV transmission. We estimated the aggregate effects that alternative policies have on population burden of disease by calculating net DALYs, which are the DALYs averted by a policy minus the health opportunity costs imposed as a result of costs incurred. Health opportunity costs are calculated using country cost-effectiveness thresholds, which represent the health gains that could be generated by alternative uses of resources.28 Country-specific thresholds are uncertain but US$500 averted per DALY is likely to be at the upper end on the basis of evidence concerning how resources would otherwise be used,29 and we used this value. We calculated net DALYs as DALYs plus costs divided by the cost-effectiveness threshold. Absolute numbers of health-related events, costs, DALYs, and net DALYs that we report are relevant for a country with a population size of around 10 million adults in 2018. We did our analysis from a health-care perspective. We discounted future costs and health outcomes to present values of 3% per annum. We assumed the costs of tenofovir, lamivudine, and dolutegravir and tenofovir, lamivudine, and efavirenz to be US$75 per year, and the cost of zidovudine, lamivudine, and a protease inhibitor (atazanavir) to be $265.30 Full details of unit costs and disability weights are provided in the appendix (p 33).
For a woman having a baby with a neural tube defect, an extra DALY was incurred for each subsequent year of the 20 year time horizon since the baby is assumed to die (ie, years lost from a child's life were valued the same as years lost from an adult's life). We assumed no monetary costs as a result of neural tube defects, except in a sensitivity analysis. Depending on an HIV-positive woman's viral load, birth of an HIV-infected child can occur. We assumed that an HIV-infected child will access ART and that an additional 0·1 DALYs, and cost of $160 per year are incurred for each subsequent year of the 20 year time horizon.
Phillips A.N., Venter F., Havlir D., Pozniak A., Kuritzkes D., Wensing A., Lundgren J.D., De Luca A., Pillay D., Mellors J., Cambiano V., Bansi-Matharu L., Nakagawa F., Kalua T., Jahn A., Apollo T., Mugurungi O., Clayden P., Gupta R.K., Barnabas R., Revill P., Cohn J., Bertagnolio S, & Calmy A. (2018). Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. The Lancet. HIV, 6(2), e116-e127.
Full text: Click here
Publication 2018
Adult Atazanavir Child Childbirth Disabled Persons dolutegravir efavirenz Hypersensitivity Infant Lamivudine Maternal-Fetal Infection Transmission Neural Tube Defects Protease Inhibitors Tenofovir Woman Zidovudine
5
Nanoparticle Morphology Analysis by SEM and TEM
Cited 6 times
Nanoparticle morphology was analyzed by scanning electron microscopy (SEM). Briefly, nanosuspensions were air dried onto a glass coverslip mounted on an SEM sample stub and sputter coated with approximately 50 nm of gold/palladium alloy. Samples were examined using a FEI Quanta 200 scanning electron microscope (Hillsboro, OR) operated at 5.0 kV. Drug loaded MDM were analyzed by transmission electron microscopy (TEM) after treatment for 8 h. Cells were washed, scraped into PBS, pelleted at 3000 r.p.m. for 8 min at room temperature, and fixed in a solution of 2% glutaraldehyde, 2% paraformaldehyde in 0.1 M Sorenson’s phosphate buffer (pH 6.2). A drop of the fixed cell suspension was placed on a formvar/silicon monoxide 200 mesh copper grid, allowed to settle for 2 min, and the excess solution wicked off and allowed to dry. A drop of NanoVan vanadium negative stain was placed on the grid for 1 min, then wicked away and allowed to dry. Grids were examined on a FEI Tecnai G2 Spirit TWIN transmission electron microscope (Hillsboro, OR) operated at 80 kV, and images were acquired digitally with an AMT digital imaging system (Woburn, MA).
Sillman B., Bade A.N., Dash P.K., Bhargavan B., Kocher T., Mathews S., Su H., Kanmogne G.D., Poluektova L.Y., Gorantla S., McMillan J., Gautam N., Alnouti Y., Edagwa B, & Gendelman H.E. (2018). Creation of a long-acting nanoformulated dolutegravir. Nature Communications, 9, 443.
Full text: Click here
Publication 2018
Aftercare Buffers Cells Copper Formvar Glutaral Gold Alloys Palladium paraform Pharmaceutical Preparations Phosphates Scanning Electron Microscopy silicon monoxide Stains Transmission Electron Microscopy Twins Vanadium

Most recents protocols related to «Dolutegravir»

1
Dolutegravir Sodium Aquasome Formulation
Not available on PMC !
This patent is related to the drug delivery system based on the aquasome. The inorganic core was prepared through calcium phosphate and stabilized through polyhydroxy oligomer on which Dolutegravir sodium drug adsorbed. The polyhydroxy oligomer comprises lactose, trehalose and sucrose. The aquasome formulation of Dolutegravir sodium improved the dissolution rate, solubility and oral bioavailability of the drug. 77
Sahu V., Sahoo S.K., & Sahoo A.C. (2024). Aquasome: As Drug Delivery Carrier in the Pharmaceutical Field. Indian Journal of Pharmaceutical Education and Research, 58(3s), s757-s767.
Publication 2024
2
Optimization of Dolutegravir Nanosuspension
Not available on PMC !
The preparation of Dolutegravir Nanosuspension (DTG NS) involved a systematic exploration of various formulation parameters using the Box-Behnken Design. Soluplus® was selected as the optimized stabilizer based on the results of preliminary studies. Three independent variables were considered: stabilizer percentage (X1), amplitude (X2), and sonication time (X3), each at three levels (-1, 0, and+1). The objective was to minimize both particle size (Y1) and polydispersibility Index (Y2). The levels of the independent variables were defined, with stabilizer percentages at 0.1%, 0.5%, and 1.0%; amplitudes at 30 W, 65 W, and 100 W; and sonication times at 3 min, 6.5 min, and 10 min. A total of 15 formulations (NS1 to NS15) were generated based on the Box-Behnken Design, each with a unique combination of stabilizer percentage, amplitude, and sonication time. The experiments were conducted following the formulated matrix, and the resulting particle sizes and polydispersibility Index values were measured [10, (link)11] . Data analysis, incorporating statistical methods, was employed to determine the optimal conditions for the preparation of DTG NS, considering the effects of independent variables on the desired formulation parameters. The formulation trials with different levels of independent variables according to box-behnken design are provided in table 1.
GOTTEMUKKULA L.D., & Raghuveer P. (2024). DEVELOPMENT AND OPTIMIZATION OF A DOLUTEGRAVIR NANOSUSPENSION USING BOX BEHNKEN DESIGN. International Journal of Applied Pharmaceutics.
Publication 2024
3
Switch to Dolutegravir or Lamivudine in Virally Suppressed Patients
Patients undergoing TT with 2 NRTIs plus a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor (NNRTI) who switched to dolutegravir plus 2 NRTIs (TT group) or to lamivudine plus dolutegravir (DT group) between December 2014 and June 2020 were eligible for study analysis if they had HIV RNA <50 copies/mL at the time of the switch and at least 1 follow-up HIV RNA determination after the switch. Exclusion criteria were the presence of a positive hepatitis B surface antigen serostatus, previous treatment with dolutegravir, and the absence of at least 1 previous genotypic resistance test result on HIV RNA.
Borghetti A., Ciccullo A., Lombardi F., Giannarelli D., Passerotto R.A., Lamanna F., Carcagnì A., Farinacci D., Dusina A., Baldin G., Zazzi M, & Di Giambenedetto S. (2024). Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed. Open Forum Infectious Diseases, 11(5), ofae198.
Full text: Click here
Publication 2024
4
Dual-drug Regimen for Virally Suppressed HIV
TANGO was a phase 3, randomized, open-label, noninferiority study designed to determine whether HIV-infected adults with virological suppression on a ≥three-drug TAF remain suppressed after switching to a 2DR of dolutegravir 50 mg/lamivudine 300 mg given once daily (10 (link)). Participants were randomized 1:1 to the dolutegravir/lamivudine regimen or current TAF, and antiviral activity was monitored over 48 weeks. In an intensive PK substudy, serial PK samples were collected in fasted state in a subset of 30 participants receiving dolutegravir/lamivudine at week 4 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose). Sparse samples were obtained without regard to food from most dolutegravir/lamivudine-assigned participants at weeks 4 (pre-dose and 1 hour post-dose), 8 (1–4 hours or 4–12 hours post-dose), 12 (4–12 hours or 1–4 hours post-dose), and weeks 24, 36, and 48 (pre-dose). Plasma samples were analyzed for dolutegravir and lamivudine concentrations using validated analytical methods based on protein precipitation followed by UHPLC-MS/MS analysis with a TurboIonSpray interface and multiple reaction monitoring. The lower limit of quantification in plasma was 20 ng/mL for dolutegravir and 2.5 ng/mL for lamivudine (9 (link)).
Chandasana H., Singh R., Adkison K., Ait-Khaled M, & Pene Dumitrescu T. (2024). Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1. Antimicrobial Agents and Chemotherapy, 68(5), e01504-23.
Full text: Click here
Publication 2024
5
Dolutegravir Concentrations in HIV
Not available on PMC !
Dolutegravir concentrations collected from October 2015 to March 2023 (n = 900) were stratified according to the main antiretroviral classes (NRTIs, NNRTIs, protease inhibitors) and according to single drugs. Dolutegravir concentrations measured in persons with HIV concomitantly treated with lamivudine were considered as the reference group.
Cattaneo D., Pagano S., Colombo M.L., Giacomelli A., Gori A, & Gervasoni C. (2024). Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations. AIDS (London, England), 38(6).
Publication 2024

Top products related to «Dolutegravir»

1
Emtricitabine by Gilead Sciences
Sourced in United States
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for the treatment of HIV-1 infection. It works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.
2
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
3
Phoenix winnonlin by Certara
Sourced in United States, Jersey, Sao Tome and Principe, Macao
Phoenix WinNonlin is a software application for data analysis in the field of pharmacokinetics and pharmacodynamics. It provides tools for modeling and simulation of drug concentration and response data.
4
Dolutegravir by MedChemExpress
Sourced in United States
Dolutegravir is a chemical compound used as a laboratory tool. It functions as an integrase inhibitor, which is a type of antiretroviral medication. Dolutegravir is utilized in research settings to study its effects and potential applications.
5
Tenofovir disoproxil fumarate by Gilead Sciences
Tenofovir disoproxil fumarate is a chemical compound used in the production of laboratory equipment. It is a salt of the antiviral drug tenofovir, which is used to treat HIV and hepatitis B infections. The compound serves as a key ingredient in the manufacturing process for certain lab equipment and instrumentation.
6
Prism 7 by GraphPad
Sourced in United States, Japan, United Kingdom, Austria, Canada, Germany, Poland, Belgium, Lao People's Democratic Republic, China, Switzerland, Sweden, Finland, Spain, France
GraphPad Prism 7 is a data analysis and graphing software. It provides tools for data organization, curve fitting, statistical analysis, and visualization. Prism 7 supports a variety of data types and file formats, enabling users to create high-quality scientific graphs and publications.
7
Dolutegravir by Selleck Chemicals
Dolutegravir is a chemical compound commonly used in laboratory settings. It serves as a key component in various research and analytical applications. The core function of Dolutegravir is to act as a pharmaceutical ingredient, particularly in the development and study of antiviral medications.
8
Dolutegravir dtg by Selleck Chemicals
Dolutegravir (DTG) is a pharmaceutical compound used in the synthesis and development of certain antiretroviral medications. It is a potent and selective inhibitor of the HIV-1 integrase enzyme, which is essential for the viral replication process. DTG can be utilized as a key ingredient or intermediate in the production of various antiretroviral drug formulations.
9
Facscalibur by BD
Sourced in United States, Germany, United Kingdom, China, Canada, Japan, Italy, France, Belgium, Switzerland, Singapore, Uruguay, Australia, Spain, Poland, India, Austria, Denmark, Netherlands, Jersey, Finland, Sweden
The FACSCalibur is a flow cytometry system designed for multi-parameter analysis of cells and other particles. It features a blue (488 nm) and a red (635 nm) laser for excitation of fluorescent dyes. The instrument is capable of detecting forward scatter, side scatter, and up to four fluorescent parameters simultaneously.
10
Dolutegravir by Gilead Sciences
Dolutegravir is an integrase inhibitor, a class of antiretroviral drugs used in the treatment of HIV infection. It functions by blocking the activity of the HIV integrase enzyme, which is responsible for integrating the viral genetic material into the host cell's DNA. This disruption prevents the virus from replicating and spreading within the body.

More about "Dolutegravir"

Dolutegravir (DTG) is a powerful antiretroviral medication used to treat human immunodeficiency virus (HIV) infection.
As an integrase strand transfer inhibitor (INSTI), it works by interfering with the HIV integrase enzyme, preventing the virus from inserting its genetic material into the host cell's DNA.
This disruption of the viral replication process helps to suppress HIV viral load and slow disease progression.
Researchers often utilize a combination of DTG with other antiretroviral drugs, such as Emtricitabine and Tenofovir disoproxil fumarate, to achieve optimal treatment outcomes.
Advanced AI-driven analysis, facilitated by tools like PubCompare.ai, allows researchers to identify the most effective and reproducible research protocols from a vast array of literature, pre-prints, and patents.
This streamlines the research process and enhances the chances of making meaningful discoveries.
The use of DMSO, a common solvent, and analysis software like Phoenix WinNonlin and GraphPad Prism 7 are also integral components of Dolutegravir research workflows.
By leveraging these resources and techniques, researchers can gain valuable insights into the pharmacokinetics, pharmacodynamics, and overall efficacy of Dolutegravir in treating HIV infection.
Overall, the combination of Dolutegravir's potent antiviral properties, advanced research methodologies, and cutting-edge analytical tools has greatly contributed to the progress in HIV treatment and management.
The continued exploration of Dolutegravir and related compounds holds promise for further advancements in the fight against this devastating disease.